HTL 18318
Alternative Names: HTL 0018318; HTL18318Latest Information Update: 02 Apr 2024
Price :
$50 *
At a glance
- Originator Heptares Therapeutics
- Developer AbbVie; Nxera Pharma
- Class Antidementias; Antipsychotics; Nootropics; Small molecules
- Mechanism of Action Muscarinic M1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Alzheimer's disease; Cognition disorders; Dementia